GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Santen Pharmaceutical Co Ltd (OTCPK:SNPHY) » Definitions » Owner Earnings per Share (TTM)

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Owner Earnings per Share (TTM) : 0.76 (As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Santen Pharmaceutical Co Owner Earnings per Share (TTM)?

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Santen Pharmaceutical Co's Owner Earnings per Share (TTM) ended in Mar. 2024 was $0.76. It's Price-to-Owner-Earnings ratio for today is 12.87.


The historical rank and industry rank for Santen Pharmaceutical Co's Owner Earnings per Share (TTM) or its related term are showing as below:

SNPHY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 10.62   Med: 20.21   Max: 652
Current: 12.88


During the past 13 years, the highest Price-to-Owner-Earnings ratio of Santen Pharmaceutical Co was 652.00. The lowest was 10.62. And the median was 20.21.


SNPHY's Price-to-Owner-Earnings is ranked better than
79.38% of 422 companies
in the Drug Manufacturers industry
Industry Median: 27.9 vs SNPHY: 12.88

Santen Pharmaceutical Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was $0.00. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $0.51. It's PE Ratio ratio for today is 19.26.

Santen Pharmaceutical Co's EPS without NRI for the three months ended in Mar. 2024 was $0.00. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2024 was $0.51. It's PE Ratio without NRI ratio for today is 19.26.


Santen Pharmaceutical Co Owner Earnings per Share (TTM) Historical Data

The historical data trend for Santen Pharmaceutical Co's Owner Earnings per Share (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santen Pharmaceutical Co Owner Earnings per Share (TTM) Chart

Santen Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Owner Earnings per Share (TTM)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.92 -0.07 0.76 -0.24 0.76

Santen Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Owner Earnings per Share (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.24 -0.24 0.53 0.93 0.76

Competitive Comparison of Santen Pharmaceutical Co's Owner Earnings per Share (TTM)

For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Santen Pharmaceutical Co's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Santen Pharmaceutical Co's Price-to-Owner-Earnings falls into.



Santen Pharmaceutical Co Owner Earnings per Share (TTM) Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

To make it simple, then you will have:

Owner Earnings per Share (TTM) = (Net Income + Depreciation, Depletion and Amortization + Change In Deferred Tax - 5Y Average of Maintenance Capital Expenditure + Change In Working Capital) / Shares Outstanding (Diluted Average)

Santen Pharmaceutical Co's Owner Earnings per Share (TTM) Calculation:

TTM / Last Quarter Average of Last 20 Quarters
Net Income 185
Depreciation, Depletion and Amortization 125
Change In Deferred Tax 23
5Y Average of Maintenance Capital Expenditure 162
Change In Working Capital 95
Shares Outstanding (Diluted Average) 365

1. Start with "Net Income" from income statement. Santen Pharmaceutical Co's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was $185 Mil.

2. "Depreciation, Depletion and Amortization" is from cashflow statement. Santen Pharmaceutical Co's Depreciation, Depletion and Amortization for the trailing twelve months (TTM) ended in Mar. 2024 was $125 Mil. This needs to be added back because company does not actually need to pay cash for it. It is a non-cash item.

3. Other non-cash charges usually include "Stock Based Compensation" and "Change In Deferred Tax":
However, to be conservative, GuruFocus will not add Stock Based Compensation back to net income. Santen Pharmaceutical Co's Change In Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2024 was $23 Mil.

4. Average maintenance capital expenditure over a business/industry cycle: 5-Year Average Maintenance Capital Expenditure = $162 Mil

It is usually best to take a long-term average of maintenance capital expenditure. Ideally this would be as long as 10 years and include at least one economic downturn. However, since many companies do not have as long as 10-year history, here GuruFocus uses the latest 5 years data to do the calculation. To smooth out unusual years but reflect recent developments, we take an average of the 5 year maintenance capital expenditure.

The following shows how to get maintenance capital expenditure.

First, calculate the revenue change regarding to the previous quarter. If the revenue decreased from the previous quarter, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
Second, if the revenue increased from the previous quarter, then calculate the percentage of Net PPE as of corresponding Revenue.
Growth Capital Expenditure = Percentage of Property, Plant and Equipment as of corresponding Revenue * Revenue Increase
Third, calculate Capital Expenditure (positive) - Growth Capital Expenditure.
If [Capital Expenditure (positive) - Growth Capital Expenditure] was negative, then the Maintenance Capital Expenditure = Capital Expenditure (positive).
If [Capital Expenditure (positive) - Growth Capital Expenditure] was positive, then the Maintenance Capital Expenditure = Capital Expenditure (positive) - Growth Capital Expenditure.
Fourth, get the average of the 5 years maintenance capital expenditure.

Santen Pharmaceutical Co's 5-Year Average Maintenance Capital Expenditure = $162 Mil

5. "Change In Working Capital" is from cashflow statement. Santen Pharmaceutical Co's Change In Working Capital for the trailing twelve months (TTM) ended in Mar. 2024 was $95 Mil.
Note: GuruFocus' Change in Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And sometimes it includes non-current parts of assets and liabilities.

6. Santen Pharmaceutical Co's Shares Outstanding (Diluted Average) for the months ended in Mar. 2024 was 364.515 Mil.

Santen Pharmaceutical Co's Onwer Earnings Per Share for Mar. 2024 is calculated as:

Owner Earnings per Share (TTM)
=( Net Income+Depreciation, Depletion and Amortization+Change In Deferred Tax
=( 184.756 +124.648+22.945
-5Y Avg of Maintenance CAPEX+Change In Working Capital )/Shares Outstanding (Diluted Average)
-161.72747077964+95.432)/364.515
=0.76

Price-to-Owner-Earnings=Current Price/Owner Earnings per Share (TTM)
=9.7822/0.76
=12.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Assumption: Companies usually do not report maintenance capital expenditures and growth capital expenditures separately. Here we use estimated numbers and average them over 5 years. The method to estimate maintenance capital expenditures can be found in above part 4.

Note: GuruFocus' Change In Working Capital is provided by Morningstar. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement from original financial report. And it includes non-current parts of assets and liabilities.


Santen Pharmaceutical Co Owner Earnings per Share (TTM) Related Terms

Thank you for viewing the detailed overview of Santen Pharmaceutical Co's Owner Earnings per Share (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Santen Pharmaceutical Co (Santen Pharmaceutical Co) Business Description

Traded in Other Exchanges
Address
Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka, JPN, 530-8552
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company reports two primary operating segments: prescription ophthalmic pharmaceuticals and other. The pharmaceuticals segment includes over-the-counter pharmaceuticals, while the other segment includes medical devices. The vast majority of Santen's revenue is derived from its prescription ophthalmic pharmaceuticals segment, which manufactures and distributes prescription and OTC pharmaceuticals. Most of Santen's sales are generated in Japan, followed by other Asian countries.

Santen Pharmaceutical Co (Santen Pharmaceutical Co) Headlines

From GuruFocus

Matthews Japan Fund 1st-Quarter Commentary

By Sydnee Gatewood Sydnee Gatewood 04-23-2020

Matthews Japan Fund Comments on Santen Pharmaceutical

By Sydnee Gatewood Sydnee Gatewood 04-23-2020